Cefiderocol
Antibiotic / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Cefiderocol?
Summarize this article for a 10 year old
Cefiderocol, sold under the brand name Fetroja among others, is an antibiotic used to treat complicated urinary tract infections when no other options are available.[5] It is indicated for the treatment of multi-drug-resistant Gram-negative bacteria including Pseudomonas aeruginosa.[6][7][8] It is given by injection into a vein.[1]
Clinical data | |
---|---|
Trade names | Fetroja, Fetcroja |
Other names | RSC-649266 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a620008 |
License data | |
Routes of administration | Intravenous infusion |
Drug class | Siderophore cephalosporins |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 56–58%[4] |
Elimination half-life | 2.8 hours |
Excretion | mainly kidney (60–70% unchanged) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C30H34ClN7O10S2 |
Molar mass | 752.21 g·mol−1 |
3D model (JSmol) | |
| |
|
Common side effects include diarrhea, infusion site reactions, constipation and rash.[9]
Cefiderocol is in the cephalosporin family of medications.[5][10] It was approved for medical use in the United States in November 2019, and in the European Union in April 2020.[5][11][2] In September 2020, cefiderocol (Fetroja) received FDA approval[12] as supplemental New Drug Application (sNDA) for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) when caused by Gram-negative bacteria resistant to other antibiotics. It is on the World Health Organization's List of Essential Medicines.[13]